PH31337A - Aerosol drug formulations containing polyglycolyzed glyceride. - Google Patents

Aerosol drug formulations containing polyglycolyzed glyceride.

Info

Publication number
PH31337A
PH31337A PH51173A PH51173A PH31337A PH 31337 A PH31337 A PH 31337A PH 51173 A PH51173 A PH 51173A PH 51173 A PH51173 A PH 51173A PH 31337 A PH31337 A PH 31337A
Authority
PH
Philippines
Prior art keywords
formulations containing
drug formulations
aerosol drug
polyglycolyzed glyceride
polyglycolyzed
Prior art date
Application number
PH51173A
Other languages
English (en)
Inventor
Lu Mou-Ying Fu
Akwete L Adjei
Pramod K Gupta
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PH31337A publication Critical patent/PH31337A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH51173A 1994-08-26 1995-08-23 Aerosol drug formulations containing polyglycolyzed glyceride. PH31337A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/296,778 US5635159A (en) 1994-08-26 1994-08-26 Aerosol drug formulations containing polyglycolyzed glycerides

Publications (1)

Publication Number Publication Date
PH31337A true PH31337A (en) 1998-07-06

Family

ID=23143511

Family Applications (1)

Application Number Title Priority Date Filing Date
PH51173A PH31337A (en) 1994-08-26 1995-08-23 Aerosol drug formulations containing polyglycolyzed glyceride.

Country Status (9)

Country Link
US (1) US5635159A (ja)
EP (1) EP0777467B1 (ja)
JP (2) JPH10505060A (ja)
AU (1) AU3329295A (ja)
CA (1) CA2195874A1 (ja)
DE (1) DE69528769T2 (ja)
IL (1) IL114893A (ja)
PH (1) PH31337A (ja)
WO (1) WO1996006598A1 (ja)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE236617T1 (de) * 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
JP2000514085A (ja) * 1996-07-08 2000-10-24 ローヌ―プーラン・ロウラー・リミテッド 医薬シクロスポリンａエーロゾル溶液処方物
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
TW581681B (en) 1998-02-20 2004-04-01 Nektar Therapeutics Liquid crystal forms of cyclosporin
US6458338B1 (en) * 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
US6264973B1 (en) 1999-08-26 2001-07-24 Fei Enterprises, Ltd. Apparatus and method for anesthetizing the cervical region of a female
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
US6464959B1 (en) 2000-05-01 2002-10-15 Aeropharm Technology Incorporated Non-aqueous aerosol suspension comprising troglitazone, a fluid propellant, and an amino acid stabilizer
US6468507B1 (en) 2000-05-01 2002-10-22 Aeropharm Technology, Inc. Non-aqueous aerosol formulation comprising rosiglitazone maleate, a non-aqueous carrier, and an amino acid stabilizer
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
TWI290473B (en) 2000-05-10 2007-12-01 Alliance Pharma Phospholipid-based powders for drug delivery
US20030003057A1 (en) * 2000-07-07 2003-01-02 Jeffry Weers Methods for administering leuprolide by inhalation
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
FR2829028B1 (fr) * 2001-08-29 2004-12-17 Aventis Pharma Sa Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de
MXPA04003623A (es) * 2001-10-19 2004-12-02 Isotechnika Inc Nuevas formulaciones analogas de ciclosporina.
WO2003053411A1 (en) 2001-12-19 2003-07-03 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7842791B2 (en) 2002-12-19 2010-11-30 Nancy Jean Britten Dispersible pharmaceutical compositions
CA2564083C (en) * 2004-04-23 2014-02-04 Philip Morris Usa Inc. Aerosol generators and methods for producing aerosols
SI1765292T1 (en) 2004-06-12 2018-04-30 Collegium Pharmaceutical, Inc. Formulations of medicines to discourage abuse
US20070219127A1 (en) * 2006-03-20 2007-09-20 Walt John G Cyclosporin a compositions
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
WO2014036414A2 (en) 2012-08-30 2014-03-06 The Board Of Trustees Of The Leland Stanford Junior University Iron chelators and use thereof for reducing transplant failure
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1274354A (fr) * 1956-03-10 1961-10-27 Agents tensio-actifs obtenus à partir de triglycérides et polyéthylène glycol
US4851211A (en) * 1986-11-25 1989-07-25 Abbott Laboratories LHRH analog formulations
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
DE69124374T2 (de) * 1990-06-29 1997-06-19 Fisons Plc, Ipswich, Suffolk Druckaerosolzusammensetzung
HUT67445A (en) * 1991-06-10 1995-04-28 Schering Corp Aerosol formulations containing 1,1,1,2-tetrafluorethane
ATE134509T1 (de) * 1991-06-10 1996-03-15 Schering Corp Fluorchlorkohlenwasserstoffreie aerosolformulierungen
DE4230876A1 (de) * 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
EP0561166A1 (de) * 1992-03-17 1993-09-22 ASTA Medica Aktiengesellschaft Dosieraerosole enthaltend den Wirkstoff D-18024 und verwandte Strukturen
WO1994016756A1 (en) * 1993-01-29 1994-08-04 Miris Medical Corporation Intrapulmonary delivery of hormones

Also Published As

Publication number Publication date
EP0777467B1 (en) 2002-11-06
JPH10505060A (ja) 1998-05-19
WO1996006598A1 (en) 1996-03-07
CA2195874A1 (en) 1996-03-07
DE69528769D1 (de) 2002-12-12
JP2010047587A (ja) 2010-03-04
IL114893A (en) 2001-04-30
US5635159A (en) 1997-06-03
DE69528769T2 (de) 2003-07-17
JP5192473B2 (ja) 2013-05-08
EP0777467A1 (en) 1997-06-11
IL114893A0 (en) 1995-12-08
AU3329295A (en) 1996-03-22

Similar Documents

Publication Publication Date Title
PH31337A (en) Aerosol drug formulations containing polyglycolyzed glyceride.
IL116460A0 (en) Aerosol drug formulations
EG23826A (en) Pharmaceutical formulations
GB9408117D0 (en) Pharmaceutical formulations
ZA969722B (en) Pharmaceutical formulations.
GB9404248D0 (en) Pharmaceutical formulations
ZA914957B (en) Aerosol drug formulations
GB9713149D0 (en) Pharmaceutical formulations
GR3030529T3 (en) Stabilized medicinal aerosol solution formulations.
GB9612297D0 (en) Medicinal aerosol formulations
GB9620187D0 (en) Medicinal aerosol formulations
IL112897A0 (en) Aerosol drug formulations containing vitamin e
CY2293B1 (en) Slow-release pharmaceutical formulations containing mizolastin
ZA96392B (en) Pharmaceutical formulations
GB9413542D0 (en) Pharmaceutical formulations
GB9418550D0 (en) Drug formulation
ZA9510754B (en) Aerosol drug formulations
GB9500978D0 (en) Pharmaceutical formulations
ZA957349B (en) Pharmaceutical formulations.
GB9401738D0 (en) Pharmaceutical formulations
GB9408161D0 (en) Pharmaceutical formulations
GB9408163D0 (en) Pharmaceutical formulations
GB9408151D0 (en) Pharmaceutical formulations
GB9408162D0 (en) Pharmaceutical formulations
GB9408164D0 (en) Pharmaceutical formulations